Analysis

An FDA expert panel convened on December 10, 2025 recommended revising testosterone replacement therapy (TRT) labeling to remove prostate cancer contraindications, rescind Schedule III classification, and broaden indications to match professional society guidance. Panelists cited the TRAVERSE randomized trial (N = 5,246) and its NEJM 2023 results showing noninferior MACE rates for testosterone versus placebo (7.0% vs 7.3%; HR 0.96; 95% CI 0.78–1.17; P < .001 for noninferiority) and noted the FDA’s February 2025 removal of a cardiovascular black‑box warning as precedent. Speakers including Khera, Bernie and Trost argued the current FDA label conflicts with American Urological Association and Endocrine Society guidance and that the Schedule III status and prostate warnings create access barriers and stigma; the Journal of Clinical Endocrinology and Metabolism prevalence figure cited was 5.6% of men aged 30–79 with low testosterone and symptoms. They warned that restrictive regulation has pushed patients to “low‑T” clinics and less‑regulated therapies (e.g., off‑label DHEA), increasing safety and quality concerns. If regulators adopt the panel’s recommendations, expect expanded routine screening, more mainstream prescribing by primary care/urology/endocrinology, and greater demand for validated TRT products; however, timing and scope of any FDA action remain uncertain and will be the key determinant of near‑term market impact.